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Abstract 
Introduction: Antimicrobial resistance is a threatening global medical challenge.  Its prevalence is on the rise, 
more so in developing countries like Pakistan. It is pivotal to know and follow the local drug sensitivity and 
resistance pattern for effective empirical treatment of urinary tract infections. 
Objectives:  To evaluate antibiotic susceptibility and resistant patterns of different urinary pathogens in cultures 
among patients presented in a tertiary care hospital. 
Materials and Methods: A Descriptive Cross-sectional study was carried out at the Department of Nephrology 
and Microbiology Holy Family Hospital, Rawalpindi Medical University from January 2018 to July 2018. All the 
samples from patients suspected to be suffering from UTI that were ordered a urine culture by attending doctors 
were recruited for the study and were sent to the central pathology laboratory of the hospital. All urine cultures 
performed in HFH were recruited for the study including both inpatient and outpatient departments. Data were 
collected in a structured performa and were entered and analyzed in SPSS version 21.0.  
Results: 402/1216 (33.0 %) urine samples had positive bacterial growths. Females accounted for the majority of 
61.6% of cases. E.coli was the most common isolate 42.7%, followed by Klebsiella spp. 17.5%. E.coli exhibited high 
antimicrobial resistance, with the least resistance to fosfomycin 13.6%. E.coli, Klebsiella spp. and pseudomonas 
showed significant coresistance to Ceftazidime and ciprofloxacin.  
Conclusion: Emergence of high AMR in a developing country like Pakistan can have grave clinical and economic 
implications. It adversely impacts all aspects of patient care. It limits therapeutic options and leads to treatment 
failure.  
Keywords: Antimicrobial resistance, Healthcare-associated UTI, healthcare-associated infections, uropathogenic 
E. coli , extended-spectrum beta-lactamases, multidrug-resistant. 
75                                                                                   Journal of Rawalpindi Medical College (JRMC); 2020; 24(1): 74-79  
 
 
Introduction 
 
Urinary Tract Infections (UTI) are a major global 
public health issue as they are the most prevalent 
bacterial infections both in the community and in 
hospitals.1,2 Every year 150 million people suffer from 
UTI worldwide with considerable economic burden.3 
UTI can arise anywhere in the urinary tract, females 
being afflicted mostly in the form of uncomplicated 
cystits.4 One in three women will develop an antibiotic 
requiring UTI during their lifetime.5 Clinical spectrum 
of urinary tract infections includes asymptomatic 
bacteria, uncomplicated UTI, complicated UTI, 
recurrent UTI and antibiotic-resistant UTIs.6 HAUTI 
accounts for approximately 40 % of nosocomial 
infections.7 The diagnosis of UTI can be made based on 
a combination of symptoms and a positive urine 
culture.8,9 Gram-negative Enterobacteriaceae are 
common causes of both community-acquired and 
HAUTIs. Uropathogenic E.coli (UPEC) a normal gut 
commensal is responsible for almost 80% of 
uncomplicated community-acquired UTIs.10,11 UTI is 
one of the most prevalent indications for antibiotic 
prescription globally.12 UTI’s account for the most 
common antibiotic-resistant infections in primary 
health care (PHC).13  Major antibiotic consumption is 
in PHC, accounting for 75%-80% of all antibiotics 
prescribed.14 Antimicrobial resistance (AMR) arises 
when bacteria survive exposure to an antimicrobial 
that would normally kill or inhibit growth. 
Consequently, these strains continue to proliferate and 
spread, due to a lack of competition from other strains. 
This has led to the emergence of superbugs. More than 
two million infections in the US annually are caused 
by bacteria resistant to first-line antibiotics. By 2050, 10 
million lives per year will be at risk from antibiotic-
resistant infections.15 AMR is an emerging global 
menace endangering efficacy of antibiotics.16 AMR 
reduces the effectiveness of antibiotics, leading to 
increased morbidity, mortality, length of stay and 
health care expenditure.17 In developing countries, a 
paucity of expensive second-line antibiotics could 
worsen the situation. Similarly in outpatients 
resistance to commonly prescribed antibiotics for UTI 
in children is increasing, more so in developing 
countries. Non-adherence to as well as non-availability 
of local antibiotic sensitivity pattern, OTC 
antimicrobial availability, recent antibiotic exposure, 
routine and injudicious use of antibiotics all are 
contributing to AMR.19 Previous antibiotic use in 
primary health care increased the subsequent risk of 
E.coli resistance to that particular antibiotic20. For an 
antibiotic to be considered a first-line empirical 
treatment for UTI, resistance should not exceed 20% in 
the most likely infecting strain.21To combat AMR, 
regular surveillance, new effective drugs, and global 
public awareness campaigns are mandatory.3 Effective 
empirical antibiotics can only be prescribed if local 
epidemiologic data regarding the common bacteria 
and antibiotic sensitivity is available.22  
 
Materials and Methods 
 
Descriptive cross-sectional study: Samples from 
patients suspected to be suffering from UTI were 
collected and sent to the central pathology laboratory 
of the hospital. All urine cultures performed in HFH 
were recruited for the study including both inpatient 
and outpatient departments. Quantitative urine 
cultures were performed by the calibrated loop 
technique delivering approximately 0.01 ml of sample 
onto Mueller Hinton agar plates followed by 
incubating the plates at 35 -37°C for 24 hours.  The 
isolates were further identified using standard 
microbiological methods and subjected to antibiotic 
susceptibility and resistance against antibiotics by 
Kirby-Bauers disc diffusion method according to 
Clinical Laboratory Standards Institute (CLSI). The 
diameters of inhibition zones were in millimeters and 
interpreted according to the manufacturer’s 
guidelines. Significant bacteriuria was defined as 
isolation of more than 105 CFU/ml. Also positive 
culture with no more than 2 species of organisms, at 
least one of which is a bacterium of ≥ 105 CFU/ml. 
Samples with three or more pathogens were discarded 
as contamination. Antimicrobials used for antibiotic 
susceptibility/resistance testing were 
amoxicillin/clavulanic acid, amikacin, cefixime, 
cefotaxime, ceftazidime, cefepime, cotrimoxazole, 
cefoperazone-sulbactam, fluoroquinolones 
(ciprofloxacin/levofloxacin/moxifloxacin), 
fosfomycin, gentamicin, carbapenems 
(imipenem/meropenem), nitrofurantoin, and 
piperacillin/tazobactam. Gram-positive bacteria were 
also tested against cefoxitin, clindamycin, fusidic acid, 
linezolid, and vancomycin.  Data was collected in a 
structured performa and was entered and analyzed in 
SPSS version 21.0.  
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Results 
 
Out of a total of 1216 urine samples submitted, 680 
samples had no growth. Candida was positive growth 
in 60, mixed growth present in 74. A total of 402 
samples exhibited positive bacterial growth. Single 
growth was positive in 376 samples, whereas 26 
cultures plates exhibited a growth of two organisms. 
So a total of 428 organisms were tested for antibiotic 
susceptibility and resistance patterns. Out of positive 
samples, females accounted for majority 264/428 
(61.68%) cases, whereas specimens from males were 
about 164/428 (38.31%). 
Gram-negative bacteria were the most common isolate 
360/428 (84.11%), whereas Gram-positive bacteria 
accounted for 68/428 (15.88 %). Overall the most 
common organism isolated was E.coli accounting for 
183/428 (42.76%), followed by Klebsiella spp. 75/428 
(17.5%). Enterococcus spp. was the third most 
common organism 56/428 (13.06%). Acinetobacter 
accounted for 41/428 (9.58%). Coliform spp. 
comprised of 33/428 (7.71 %). Pseudomonas 
aeruginsoa was 25/284 (5.84 %). MRSA accounted for 
11/428 (2.57%). Proteus mirabilis 2/284 (0.47%), 
whereas S.aureus and Serratia marcescens each 
accounted for one case (0.23%) respectively. 
 
Table 1: Age Demographics                                           
No of Cases 430 
Mean 47.4488 
Std. Deviation 12.19369 
Minimum 16.00 
Maximum 75.00 
 
Table 2: Gender demographics 
 
 
 
 
Figure 1: Bar Chart showing frequency of various 
Uropathogens 
 
 
Figure 2: Bar Chart Showing Resistance in E.coli 
 
Figure 3: Bar Chart Showing Resistance in E.coli, 
Klebsiella, Pseudomonas & Enterococcus 
 
Gender N Percent 
Male 164 38.3 
Female 264 61.7 
Total 428 100.0 
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Discussion 
 
In our study E.coli was the most common isolate from 
urinary specimens, this is consistent with almost all 
studies reviewed.23,24,25 E.coli is emerging as an MDR 
pathogen worldover.26,27,28 In the past, MDR bacteria 
were prevalent in nosocomial/healthcare-associated 
infections. But now they are being increasingly found 
in community sources of infection. This will have dire 
consequences as AMR is associated with the poor 
patient outcomes with increased health care costs.29 
Fluoroquinolones proved to be very effective for UTI 
for many years, as resistance was very low initially. 
Unfortunately, progressive escalation in global 
quinolone resistance is a crucial development.30 WHO 
has declared E.coli as one of the major antibiotic-
resistant human pathogens from data collected from 
17 countries and documented ciprofloxacin resistance 
of UPEC from 8% to 65%. In October 2015 WHO took 
the initiative to establish the Global Antimicrobial 
Resistance Surveillance System (GLASS) to monitor 
AMR worldwide31. 
E.coli is the most common uropathogen producing 
ESBL32, an enzyme produced by bacteria inactivating β 
lactam antibiotics (penicillins, cephalosporins, and 
aztreonam).33 The global increase in the prevalence of 
ESBL producing E.coli is critical, reported higher in 
Asia compared to Europe.34 ESBL producing E.coli 
also harbor various other antimicrobial resistance 
genes rendering them resistant to other clinically 
important alternatives like aminoglycosides, 
cotrimoxazole, fluoroquinolones, trimethoprim. This 
significantly reduces therapeutic options and increases 
therapeutic failure.35,36,37 Another worrisome aspect 
increases in Carbanapemase producing E.coli, 
especially in healthcare-associated infections, 
rendering carbapenems ineffective.38 
In our study, E.coli exhibited high resistance to all 
available oral antibiotics with the least resistance to 
fosfomycin 13.8%, a drugless used in our population. 
Resistance to commonly used drugs for empiric 
treatment of UTI is as follows: amoxicillin-clavulanic 
acid 87.5%, cotrimoxazole 82.1%, ciprofloxacin 74.3%, 
cefuroxime 88.9%, cotrimoxazole 82.1% nitrofurantoin 
31.7%. Resistance to 3rd and 4th generation 
cephalosporins was above 85% Overall resistance 
observed is much higher than what has been reported 
previously. E.coli, Klebsiella spp. and pseudomonas 
exhibited significant co-resistance to ciprofloxacin and 
ceftazidime. In our study overall resistance is much 
higher than what has been reported previously in 
Pakistan. 
Ibrahim et al (2012) from Sudan reported 92.7% MDR-
UPEC, ESBL positivity 32.7%, resistance to 
cotrimoxazole 88.3%, ciprofloxacin 58.4%, 
nitrofurantoin 22.4%, cefotaxime 92.5%.28 Oluwasola et 
al (2013) from Nigeria reported UPEC with MDR 
(36.5% resistant to 10 out of 11 antimicrobials), with 
fluoroquinolone resistance ranging from 65.7—86.9%. 
Lowest resistance was observed for nitrofurantoin 
(7.3%).39 Daoud et al (2015) reported resistance as 
follows ciprofloxacin 41%, cotrimoxazole 41.6%, 
ceftazidime 30.2% nitrofurantoin 4.1%, fosfomycin 
0.4% with progressive increase in ESBL positivity, 
increasing from 1.3% in 1997 to 25.3% in 2012 in UPEC 
in Lebanese population.37. Jena et al (2016) observed 
UPEC with MDR 68.7%, having resistance to ofloxacin 
93.5%, cotrimoxazole 67.5%, cefepime/ceftriaxone 
96.1%, ceftazidime 100%, nitrofurantoin 24.6% and 
ESBL genes in 59.4%36. Alizade et al (2018) E.coli  
fluoroquinolone resistance between 5—64.7% 
cotrimoxazole 4.2—88.2%, third-generation 
cephalosporins 15 to 87%, and ESBL positivity ranging 
between 17.45 – 66.2% from different regions of Iran32. 
Woldaii et al (2016) documented E.coli resistance to 
ciprofloxacin 30%, ceftriaxone 7% in community 
antibiogram from Texas USA.23. Frazee et al (2018) 
reported ESBL genes in 5.9 % of UTI’S in ED40. 
Tandogdu et al reported 20% resistance to all 
antimicrobials in HAUTI.41 In 2014 Ali et al from 
Pakistan observed UPEC resistance as follows 
cotrimoxazole 86%, ciprofloxacin/ceftazidime 57.5%, 
cefixime 53.7%, and nitrofurantoin 3.7% in 
outpatients.42 CDDEP reported a higher Drug 
Resistance Index in developing countries because of 
higher disease burden and higher consumption of 
antibiotics.43 In 2017 CDDEP E.coli resistance map for 
Pakistan reported resistance as follows: 
aminopenicillins 97%, carbapenems 10%, 
cephalosporins (3rd Gen) 86%, fluoroquinolones 59%.43 
Overall worldwide AMR shows considerable 
geographical variation.41,43,44 AMR is coupled with a 
degree of exposure to a particular antimicrobial; 
selection pressure. This has been observed with 
fluoroquinolones and cotrimoxazole.44 Areas with high 
prescription rates for these antimicrobials developed 
correspondingly high resistance rates to these drugs. 
Avoidance or decreased exposure to a certain 
antimicrobial over years/decades can probably 
increase susceptibility.33,44 This necessitates the 
appropriate use and disposal of antimicrobials in the 
health sector as well as in the food industry (animal 
health and agriculture). WHO recommends a global 
strategic plan involving all countries to increase 
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awareness, global AMR surveillance, and infection 
prevention, and antibiotic stewardship, development 
of new antibiotics, vaccines and diagnostic tools. 
This study focused on single-center experience. Patient 
records were not available, so the distinction between 
asymptomatic bacteriuria and true infection could not 
be made. Also, the distinction between inpatient and 
outpatient samples was not possible. Data from 
HAUTI tends to exaggerate AMR.  
 
Conclusion 
  
High antibiotic resistance observed in our study can 
have far-reaching public health implications. AMR is a 
serious national and global public health challenge 
that needs continuous surveillance and resolute 
management. We need multicenter and larger-scale 
prospective studies from all over Pakistan to collect 
data and establish a central national registry. AMR can 
vary from region to region even in the same country. 
Documentation susceptibility and resistance patterns 
and adhering to them are imperative. All measures 
have to be taken to minimize community antibiotic 
exposure. 
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